Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report.

Torasawa, Masahiro; Yoshida, Tatsuya; Shiraishi, Kouya; Goto, Naoko; Ueno, Toshihide; Ichikawa, Hitoshi; Yagishita, Shigehiro; Kohsaka, Shinji; Goto, Yasushi; Yatabe, Yasushi; Hamada, Akinobu; Mano, Hiroyuki; Ohe, Yuichiro

Torasawa, Masahiro; Yoshida, Tatsuya; Shiraishi, Kouya; Goto, Naoko; Ueno, Toshihide; Ichikawa, Hitoshi; Yagishita, Shigehiro; Kohsaka, Shinji; Goto, Yasushi; Yatabe, Yasushi; Hamada, Akinobu; Mano, Hiroyuki; Ohe, Yuichiro.

Afiliación

Torasawa M; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshida T; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shiraishi K; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Goto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Ueno T; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Ichikawa H; Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Yagishita S; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kohsaka S; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Goto Y; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Yatabe Y; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Hamada A; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Mano H; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ohe Y; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

JTO Clin Res Rep ; 5(4): 100657, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38706977

ABSTRACT

ABSTRACT

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a "disease flare." This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.

Palabras clave

Case report; Disease flare; Lenvatinib; Thymic carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google